GlobalData highlights value of using new cell and gene editing tech

A new industry report highlights the importance of introducing novel technologies early in the cell line development and production processes.

GlobalData says that contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) must introduce tech - such as the highly touted CRISPR gene editing technique - at an earlier stage to maximize value.

Editor in chief Peter Shapiro said: “Other gene-editing techniques, such as recombinant adeno-associated virus (rAAV) and Transposon technologies may also see increased use as the biologics industry moves forward into new types of cell-based products.”